Ondansetron treatment in patients with Tourette's syndrome

P. Toren*, N. Laor, D. J. Cohen, L. Wolmer, A. Weizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Ondansetron, a selective 5-HT3 antagonist, may lower mesolimbic dopaminergic hyperactivity. The present open-label pilot study evaluated the effect of ondansetron in Tourette's syndrome. Six Tourette's syndrome men aged 14-48 years resistant to haloperidol participated in the study. Assessments included the Yale Global Tic Severity Scale (YGTSS), Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), and Tourette's syndrome-Clinical Global Impression (TS-CGI) scale. The maximal ondansetron dosage (8-16 mg per day) was given for 3 weeks. Ondansetron treatment was associated with a significant decrease in the severity of tics. Two patients showed a definite response (score improvement of 40% or more), and two showed a probable response (> 25%). Two patients did not improve. Side-effects were transient and included abdominal pain (n = 5) and constipation (n = 2). Ondansetron may possess anti-tic effects in some Tourette's syndrome patients.

Original languageEnglish
Pages (from-to)373-376
Number of pages4
JournalInternational Clinical Psychopharmacology
Issue number6
StatePublished - 1999


  • Dopamine
  • Obsessive-compulsive disorder
  • Ondansetron
  • Serotonin
  • Tourette's syndrome


Dive into the research topics of 'Ondansetron treatment in patients with Tourette's syndrome'. Together they form a unique fingerprint.

Cite this